doc_id	sent_index	relation_id	relation	trigger	trigger_offset	arg_num	arg_base_np	arg_protein	arg_domain	arg_site	arg_sugar	PSource	SiteSource	NProtein	NID	SiteName	sent_text
33073321	1	12	gly	Zr-MOF	252:257	arg1	A hydrophilic carbohydrate functionalized magnetic metal organic framework	MOF@G6P			A hydrophilic carbohydrate functionalized magnetic metal organic framework	OGER		MOF@G6P	Q9H7Z6		A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	1	54	gly	@	258:258	arg1	A hydrophilic carbohydrate functionalized magnetic metal organic framework	MOF@G6P			A hydrophilic carbohydrate functionalized magnetic metal organic framework	OGER		MOF@G6P	Q9H7Z6		A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	1	71	gly	Mag	248:250	arg1	A hydrophilic carbohydrate functionalized magnetic metal organic framework	Mag			A hydrophilic carbohydrate functionalized magnetic metal organic framework	OGER		Mag	P20916		A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
35670884	9	27	gly	fucosylation	1407:1418	arg1	SPARC	SPARC				PUBTATOR		SPARC	6678		These findings provide a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD.
35670884	9	38	gly	SPARC	1423:1427	arg1	core fucosylation	SPARC			core fucosylation	PUBTATOR		SPARC	6678		These findings provide a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD.
36370046	3	49	gly	protein	537:543	arg1	the glycan heterogeneity	spike protein			the glycan heterogeneity	PUBTATOR		spike protein	43740568		Analytical reports have described the glycan heterogeneity of the spike protein.
36370046	3	67	gly	heterogeneity	510:522	arg1	the spike protein	the spike protein				PUBTATOR		spike protein	43740568		Analytical reports have described the glycan heterogeneity of the spike protein.
33231560	9	56	gly	RIPK3	1887:1891	arg1	OGT mediated O-GlcNAcylation	RIPK3			OGT mediated O-GlcNAcylation	PUBTATOR		RIPK3	246240		However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
35247653	0	52	gly	hyposialylated	23:36	arg1	a novel hyposialylated erythropoietin	a novel hyposialylated erythropoietin				PUBTATOR		erythropoietin	2056		Characterizing a novel hyposialylated erythropoietin by intact glycoprotein and glycan analysis.
35484857	4	19	gly	TNF-α	852:856	arg1	the LPS/D-GalN-triggered production	TNF-α, IL-1β,			the LPS/D-GalN-triggered production	PUBTATOR		TNF-α, IL-1β,	7124		HPS-50 significantly decreased the levels of ALT, AST, MPO, and MDA, increased the activities of SOD, CAT, and GSH, and suppressed the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05).
35484857	4	23	gly	IL-1β	859:863	arg1	the LPS/D-GalN-triggered production	TNF-α, IL-1β,			the LPS/D-GalN-triggered production	PUBTATOR		TNF-α, IL-1β,	7124		HPS-50 significantly decreased the levels of ALT, AST, MPO, and MDA, increased the activities of SOD, CAT, and GSH, and suppressed the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05).
35484857	4	58	gly	IL-6	870:873	arg1	the LPS/D-GalN-triggered production	IL-6			the LPS/D-GalN-triggered production	PUBTATOR		IL-6	3569		HPS-50 significantly decreased the levels of ALT, AST, MPO, and MDA, increased the activities of SOD, CAT, and GSH, and suppressed the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05).
32417172	6	85	gly	glycosylation	1053:1065	arg1	p53	p53			glycosylation	OGER		p53	P04637		METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
37271268	5	43	gly	contained	811:819	arg1	LNP-2 AND an additional 1,4-Glc glycosidic linkage	LNP-2			an additional 1,4-Glc glycosidic linkage	OGER		LNP	Q9C0E8		Additionally, LNP-2 contained an additional 1,4-Glc glycosidic linkage in comparison to LNP-1.
34804021	5	76	gly	IgG	1001:1003	arg1	N-glycan biosynthesis	IgG			N-glycan biosynthesis	PUBTATOR		IgG	16059		Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
36244450	0	85	gly	N-glycosylation	0:14	arg1	CD206	CD206				PUBTATOR		CD206	4360		N-glycosylation of mannose receptor (CD206) regulates glycan binding by C-type lectin domains.
33801653	7	48	gly	4E-BP1	1433:1438	arg1	the S5A/S6A O-GlcNAcylation-site mutant	4E-BP1			the S5A/S6A O-GlcNAcylation-site mutant	PUBTATOR		4E-BP1	1978		Further analyses revealed that the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) contributes to the downregulation of OGT induced by hyper-O-GlcNAcylation; the S5A/S6A O-GlcNAcylation-site mutant of 4E-BP1 cannot support this regulation, suggesting an important role of O-GlcNAcylation.
36239409	6	66	gly	NN015840T	1501:1509	arg1	the acidic O-specific polysaccharide	NN015840T			the acidic O-specific polysaccharide	Cterm		NN015840T			The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36894060	10	59	gly	alte	1335:1338	arg1	polysaccharides	alte			polysaccharides	OGER		alte	O96006		These results will provide insights into specific structures and functions of polysaccharides from the V. alte.
36940546	1	13	gly	-Rhap-	230:235	arg1	a novel 28.6 kDa acidic polysaccharide	Rhap-(1			a novel 28.6 kDa acidic polysaccharide	OGER		Rhap-(1			In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	26	gly	1 → and → 3,6	237:249	arg1	a novel 28.6 kDa acidic polysaccharide	3,6)-Galp			a novel 28.6 kDa acidic polysaccharide	OGER		3,6)-Galp	Q9UBC7		In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	32	gly	-Galp-	251:256	arg1	a novel 28.6 kDa acidic polysaccharide	3,6)-Galp			a novel 28.6 kDa acidic polysaccharide	OGER		3,6)-Galp	Q9UBC7		In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
33609912	2	83	gly	glycosylation	424:436	arg1	both neutralizing and non-neutralizing IgG1	both neutralizing and non-neutralizing IgG1				OGER		IgG1	P01857		As changes in the antibody's carbohydrate chain can interfere with its effector functions, we compared the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies and analyzed their influence on in vitro antibody neutralizing activities.
34957216	7	43	gly	glycoproteins	1163:1175	arg1	their S glycoproteins	their S glycoproteins				PUBTATOR		S glycoproteins	43740568		For example, G839W of SARS-CoV-1 corresponds to G857W of SARS-CoV-2, which decrease the stability of their S glycoproteins.
36972173	5	23	gly	present	682:688	arg1	SARS-CoV-2 AND the 22 N-linked glycan attachment sites	SARS-CoV-2			the 22 N-linked glycan attachment sites	OGER		SARS	P49591		Of the 22 N-linked glycan attachment sites present on SARS-CoV-2, 15 are shared by all 12 sarbecoviruses.
36159782	8	62	gly	containing	1376:1385	arg1	the IgG AND two Man5	the IgG			two Man5	Cterm		IgG			Man5 glycans resulted in decreased binding compared to complex-type glycans, with the lowest binding for the IgG containing two Man5.
37294165	10	24	gly	non-glycosylated	1626:1641	arg1	non-glycosylated SPINK13	non-glycosylated SPINK13				OGER		SPINK13	Q1W4C9		Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	10	45	gly	glycosylated	1747:1758	arg1	glycosylated SPINK13	glycosylated SPINK13				OGER		SPINK13	Q1W4C9		Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	10	54	gly	non-glycosylated	1692:1707	arg1	non-glycosylated SPINK-13	non-glycosylated SPINK-13				OGER		SPINK-13	Q1W4C9		Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	10	69	gly	glycosylated	1601:1612	arg1	glycosylated SPINK13	glycosylated SPINK13				OGER		SPINK13	Q1W4C9		Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
36529080	9	1	gly	glycosylation	1356:1368	arg1	Dectin-1	Dectin-1				PUBTATOR		Dectin-1	64581		we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
35678155	3	63	gly	had	725:727	arg1	APS2 AND galacturonic acid	APS2			galacturonic acid	OGER		APS2	Q8NFP7		Results indicated that the two kinds of APS had the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1.
37218360	14	6	gly	glycoforms	1845:1854	arg1	optimal antibody and CD16a glycoforms	optimal antibody and CD16a glycoforms				OGER		CD16a	P08637		Furthermore, optimal antibody and CD16a glycoforms are defined that provide the greatest ADCC activity.
34911982	0	67	gly	afucosylated	35:46	arg1	afucosylated IgG	afucosylated IgG				PUBTATOR		IgG	668542		A functional spleen contributes to afucosylated IgG in humans.
36329887	11	73	gly	glycoforms	2172:2181	arg1	FSH glycoforms	FSH glycoforms				OGER		FSH			Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
35713525	7	31	gly	N-glycan	874:881	arg1	Asn-51			Asn-51	Asn-51		SpecificSite			Asn-51	Although intracellular proteins usually harbor core-type N-glycans, the N-glycan on Asn-51 of Csh1 exhibited a unique mannan-like structure containing a long backbone of mannose.
35370997	9	96	gly	released	2168:2175	arg1	IgG AND N-glycans	IgG			N-glycans	Cterm		IgG			N-glycans were released from IgG by PNGase F digestion and analyzed by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) after 2-aminobenzamide (2-AB) labeling.
34154738	3	9	gly	FUT	560:562	arg1	2- fluoro peracetylated fucose	FUT			2- fluoro peracetylated fucose	PUBTATOR		FUT	100689278		The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
36131913	3	24	part_of	FcγRIIIa	750:757	arg1	Ile158	FcγRIIIa		Ile158 and Val158		PUBTATOR	AminoAcid	FcγRIIIa	2214	Ile158 and Val158	In contrast to humans, macaques only have one low affinity FcγRIII receptor, CD16, which shares a polymorphism at position 158 with human FcγRIIIa with Ile158 and Val158 variants.
36648436	1	6	gly	sialylated	215:224	arg1	STn	STn				PUBTATOR		STn	1917		In epithelial cancers, truncated O-glycans, such as the Thomson-nouveau antigen (Tn) and its sialylated form (STn), are up-regulated on the cell surface and associated with poor prognosis and immunological escape.
32531122	8	21	gly	IgG	1015:1017	arg1	N-linked glycosyl residues	IgG			N-linked glycosyl residues	Cterm		IgG			Furthermore, we show that removal of N-linked glycosyl residues from these IgG did not interfere with its entry into the podocytes but eliminated its ability to upregulate CAMK4 and cause podocyte injury.
35021101	2	50	gly	glycosylated	314:325	arg1	glycosylated HIV Env-immunogen NPs	glycosylated HIV Env-immunogen NPs				OGER		NPs	P0C0P6		We recently reported that mannose-binding lectin (MBL) triggers trafficking of glycosylated HIV Env-immunogen NPs to lymph node follicles.
34957216	10	23	gly	glycoprotein	1552:1563	arg1	the S glycoprotein	the S glycoprotein				PUBTATOR		S glycoprotein	43740568		We further predicted that many mutations on N-linked glycosylation sites would increase the stability of the S glycoprotein.
36135182	9	5	gly	N-glycosylation	1123:1137	arg1	DSPAα2	DSPAα2				PUBTATOR		DSPAα2	112321404		This study confirms that N-glycosylation affects the biochemical function of DSPAα2, which provides a reference for subsequent applications of DSPAα2.
36585837	11	77	gly	glycosylated	1616:1627	arg1	PIGR	PIGR				PUBTATOR		PIGR	397315		PIGR (polymeric immunoglobulin receptor) was the most glycosylated protein with 14 sites identified.
33592173	5	16	gly	glycosylates	766:777	arg1	TOM70	TOM70				OGER		TOM70	O94826		Phosphorylated OGT glycosylates TOM70 on Ser94, enhancing MIC19 protein import into mitochondria and promoting cristae formation and respiration.
35370997	14	29	gly	N-glycosylation	3054:3068	arg1	IgG	IgG				Cterm		IgG			Our results suggest that N-glycosylation of IgG undergoes dynamic changes during the intensification of thyroiditis in HT, and that in GD autoimmunity it is affected significantly by immunosuppressive therapy.
35309324	7	30	gly	glycosylation	1286:1298	arg1	PD-1	PD-1				PUBTATOR		PD-1	Q15116		These results indicate that both the binding and blocking efficacy of cemiplimab require the N58 glycosylation of PD-1.
36870092	10	7	gly	protein	1577:1583	arg1	bisecting GlcNAc	p38-interacting protein			bisecting GlcNAc	OGER		p38-interacting protein	Q8NEM7		Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	10	17	gly	beta-5	1667:1672	arg1	β1,6-branching N-glycan	integrin beta-5			β1,6-branching N-glycan	OGER		integrin beta-5	P18084		Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
35507105	0	65	gly	O-glycosylated	76:89	arg1	O-glycosylated insulin	O-glycosylated insulin				PUBTATOR		insulin	3630		Identifying signatures of proteolytic stability and monomeric propensity in O-glycosylated insulin using molecular simulation.
37037133	2	58	gly	glycoproteins	347:359	arg1	MFGM glycoproteins	MFGM glycoproteins				OGER		MFGM glycoproteins	Q08431		However, information on site-specific N-glycosylation of MFGM glycoproteins in donkey and human milk remains limited.
37037133	2	78	gly	N-glycosylation	323:337	arg1	MFGM glycoproteins	MFGM glycoproteins				OGER		MFGM glycoproteins	Q08431		However, information on site-specific N-glycosylation of MFGM glycoproteins in donkey and human milk remains limited.
34012659	15	96	gly	N-glycosylation	2040:2054	arg1	BST-2	BST-2				PUBTATOR		BST-2	684		CONCLUSIONS Our findings illuminate the novel function of BST-2 as an oncogene of HBV-associated HCC, and highlight the novel relationship of N-glycosylation of BST-2 in regulating HCC tumorigenesis in vitro.
36580234	7	22	part_of	PD-L1	1176:1180	arg1	Asn-192	PD-L1		Asn-192 and Asn-200		PUBTATOR	SpecificSite	PD-L1	29126	Asn-192 and Asn-200	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
34878920	7	23	gly	glycosylated	1126:1137	arg1	the heavily glycosylated envelope protein	the heavily glycosylated envelope protein				PUBTATOR		envelope protein	64006		Among all the viral proteins, the heavily glycosylated envelope protein is especially crucial.
36565355	7	39	gly	EGF27	818:822	arg1	the O-fucose site	EGF27			the O-fucose site	Cterm		EGF27	13645		It has been shown that the loss of the O-fucose site of EGF27 alters NOTCH1 activity.
37121976	2	18	gly	composition	455:465	arg1	LRG1	LRG1			composition	OGER		LRG1	P02750		Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
36189205	6	17	gly	afucosylated	1115:1126	arg1	afucosylated IgG1	afucosylated IgG1				OGER		IgG1	P01857		Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
36189205	6	47	gly	found	1220:1224	arg1	FcγRIIIa AND a glycan structure	FcγRIIIa			a glycan structure	PUBTATOR		FcγRIIIa	2214		Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
32417172	4	31	gly	glycosylated	573:584	arg1	the tumor suppressor p53	the tumor suppressor p53				OGER		tumor suppressor p53	P04637		Previously, we reported the tumor suppressor p53 could be O-GalNAc glycosylated in vitro.
32409323	5	73	gly	FBXO6	701:705	arg1	transgenic Col2a1-CreER mice	FBXO6			transgenic Col2a1-CreER mice	PUBTATOR		FBXO6	50762		The role of FBXO6 in cartilage degeneration was analysed with global FBXO6 mice, transgenic Col2a1-CreER mice.
36435009	0	31	gly	core-fucosylated	24:39	arg1	core-fucosylated glycan-preferred ENGase	core-fucosylated glycan-preferred ENGase				OGER		ENGase	Q8NFI3		A fluorogenic probe for core-fucosylated glycan-preferred ENGase.
36014368	7	70	gly	N-glycosylation	1002:1016	arg1	the S protein	the S protein				PUBTATOR		S protein	Q15517		In this work, the N-glycosylation status of the S protein within virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana) was investigated using a glycoproteomic approach.
32592613	7	50	gly	glycosylation	1160:1172	arg1	IGFBP-3	IGFBP-3				OGER		IGFBP-3	P17936		Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
35211008	0	8	gly	N-Glycosylation	130:144	arg1	β1AR	β1AR				PUBTATOR		1	12044		Stachytine Hydrochloride Improves Cardiac Function in Mice with ISO-Induced Heart Failure by Inhibiting the α-1,6-Fucosylation on N-Glycosylation of β1AR.
34012659	11	85	gly	non-N-glycosylated	1444:1461	arg1	BST-2	BST-2				PUBTATOR		BST-2	684		We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
35713525	6	24	gly	N-glycan	731:738	arg1	Asn-224			Asn-224	Asn-224		SpecificSite			Asn-224	Sur1 carries an N-glycan on Asn-224, whereas Csh1 has N-glycans on Asn-51 and Asn-247.
35713525	6	8	gly	carries	720:726	arg1	Sur1 AND an N-glycan	Sur1			an N-glycan	PUBTATOR		Sur1	856050		Sur1 carries an N-glycan on Asn-224, whereas Csh1 has N-glycans on Asn-51 and Asn-247.
35713525	6	46	gly	has	765:767	arg1	Csh1 AND N-glycans	Csh1			N-glycans	PUBTATOR		Csh1	852458		Sur1 carries an N-glycan on Asn-224, whereas Csh1 has N-glycans on Asn-51 and Asn-247.
36809652	7	46	gly	apo	1401:1403	arg1	intact O-glycan structures	apo(a			intact O-glycan structures	OGER		apo(a	P08519		We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	7	10	gly	de-O-glycosylated	1460:1476	arg1	de-O-glycosylated apo	apo(a				OGER		apo(a	P08519		We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
32340215	1	4	gly	glycoprotein	172:183	arg1	MAG	MAG				PUBTATOR		MAG	4099		Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	1	4	gly	glycoprotein	172:183	arg1	encoding myelin-associated glycoprotein	glycoprotein (MAG)				PUBTATOR		glycoprotein (MAG)	4099		Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
35470665	8	46	gly	epitopes	1432:1439	arg1	gp120	gp120			epitopes	PUBTATOR		gp120	3700		These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
33515675	0	50	gly	NOTCH1	57:62	arg1	O-GlcNAcylation	NOTCH1			O-GlcNAcylation	PUBTATOR		NOTCH1	4851		SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer.
37121976	6	51	gly	deglycosylated	1200:1213	arg1	deglycosylated LRG1	deglycosylated LRG1				OGER		LRG1	P02750		Moreover, the intracavernous administration of deglycosylated LRG1 in a diabetic mouse model ameliorated vascular and neurological abnormalities and restored erectile function.
34674311	7	88	gly	glycosylation	1194:1206	arg1	TMEM43S358L	TMEM43S358L				PUBTATOR		TMEM43	79188		Intriguingly, the specific glycosylation of TMEM43S358L resulted from the altered membrane topology of TMEM43.
34276694	0	100	gly	Glycosylation	31:43	arg1	Interleukin-7	Interleukin-7				PUBTATOR		Interleukin-7	3574		Internal Disulfide Bonding and Glycosylation of Interleukin-7 Protect Against Proteolytic Inactivation by Neutrophil Metalloproteinases and Serine Proteases.
32273875	2	42	gly	carbohydrates	251:263	arg1	factor VIII	factor VIII			carbohydrates	PUBTATOR		factor VIII	14069		Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes.
36809652	5	27	gly	apo	894:896	arg1	the O-glycan structures	apo(a			the O-glycan structures	OGER		apo(a	P08519		Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	5	14	gly	structures	880:889	arg1	a	Lp(a			structures	OGER		Lp(a	P08519		Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36637420	3	2	gly	HAI-2	506:510	arg1	The N-glycan moiety	HAI-2			The N-glycan moiety	PUBTATOR		HAI-2	10653		The N-glycan moiety of HAI-2 can function as a subcellular targeting signal.
35995381	10	31	gly	thyroglobulin	1529:1541	arg1	N-glycans	thyroglobulin			N-glycans	PUBTATOR		thyroglobulin	7038		BIOLOGICAL SIGNIFICANCE: N-glycans of human thyroglobulin modulate thyroid hormone synthesis both in vivo and in vitro.
34735575	0	96	gly	glycosylation	33:45	arg1	SARS-CoV-2	SARS-CoV-2				OGER		SARS	P49591		Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants.
36493594	5	28	gly	RESULTS	977:983	arg1	IgG	IgG			RESULTS	Cterm		IgG			RESULTS The 21 N-glycans in fetuin and another 21 N-glycans in IgG by either PF-ProA or PA-ProA were identified using LC-MS/MS.
36329887	4	10	gly	F1-deglycosylated	711:727	arg1	Endoglycosidase F1-deglycosylated FSH	Endoglycosidase F1-deglycosylated FSH				OGER		FSH			Endoglycosidase F1-deglycosylated FSH bound to the complete extracellular domain of the FSH receptor crystallized as a trimeric complex.
36159782	6	28	gly	non-glycosylated	1104:1119	arg1	the non-glycosylated IgG1	the non-glycosylated IgG1				OGER		IgG1	P01857		The LALA-PG mutated antibody showed no binding to the FcγIIa receptor (excluding potential non-specific binding effects) while the non-glycosylated IgG1 showed a strongly reduced, but still minor binding.
35380435	1	48	gly	glycosylated	213:224	arg1	the heavily glycosylated spike protein	the heavily glycosylated spike protein				PUBTATOR		spike protein	43740568		SARS-CoV-2 cellular infection is mediated by the heavily glycosylated spike protein.
36637420	5	24	part_of	contains	896:903	arg1	HAI-2 AND two putative N-glycosylation sites	HAI-2		sites, Asn-57 and Asn-94		PUBTATOR	SpecificSite	HAI-2	10653	sites, Asn-57 and Asn-94	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	5	24	part_of	contains	896:903	arg1	HAI-2 AND Asn-94	HAI-2		sites, Asn-57 and Asn-94		PUBTATOR	SpecificSite	HAI-2	10653	sites, Asn-57 and Asn-94	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	5	24	part_of	contains	896:903	arg1	HAI-2 AND Asn-94	HAI-2		sites, Asn-57 and Asn-94		PUBTATOR	SpecificSite	HAI-2	10653	sites, Asn-57 and Asn-94	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36206406	4	41	gly	modified	677:684	arg3	AlpA/B AND glycans	AlpA/B			glycans	PUBTATOR		AlpA/B	None		Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	4	41	gly	modified	677:684	arg1	BabA/B AND glycans	BabA/B			glycans	PUBTATOR		BabA/B	None		Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
33199824	10	45	gly	O-GlcNAcylation	1191:1205	arg1	SMAD4 Thr63	SMAD4			O-GlcNAcylation	PUBTATOR		SMAD4	4089		As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33801653	5	58	gly	OGT	937:939	arg1	the O-GlcNAc-feedback regulation	OGT			the O-GlcNAc-feedback regulation	PUBTATOR		OGT	8473		In this study, we investigated the O-GlcNAc-feedback regulation of OGT and OGA expression in lung cancer cells.
35344340	2	20	gly	aglycosylated	497:509	arg1	aglycosylated Fc ADC variants	aglycosylated Fc ADC variants				OGER		Fc ADC variants	Q6ZQY3		We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
36716113	6	84	gly	IgG1	1237:1240	arg1	maximal, minimally opposed, pro-inflammatory glycan profiles	IgG1			maximal, minimally opposed, pro-inflammatory glycan profiles	OGER		IgG1	P01857		In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
34650217	5	28	gly	modified	831:838	arg3	KAT5 AND O-GlcNAcylation	KAT5			O-GlcNAcylation	OGER		KAT5	Q8CHK4		Specifically, lysine acetyltransferase 5 (KAT5), belonging to the MYST family of histone acetyltransferases (HAT), is highly modified by O-GlcNAcylation in PCK1 knockout hepatoma cells.
35234142	0	54	gly	transglycosylation	35:52	arg1	the GH5_5 endo-1,4-β-glucanase RBcel1	the GH5_5 endo-1,4-β-glucanase RBcel1				Cterm		RBcel1			Highlighting the factors governing transglycosylation in the GH5_5 endo-1,4-β-glucanase RBcel1.
35995381	0	47	gly	N-glycosylation	14:28	arg1	human thyroid thyroglobulin	human thyroid thyroglobulin				PUBTATOR		thyroglobulin	7038		Site-specific N-glycosylation analysis of human thyroid thyroglobulin by mass spectrometry-based Glyco-analytical strategies.
32993960	4	18	part_of	HAS2	825:828	arg1	the Thr328 position	HAS2		the Thr328 position		PUBTATOR	SpecificSite	HAS2	3037	Thr328 position	We identified a phosphorylation site at the position corresponding to the Thr328 position of full-length HAS2, which was detected in the cells regardless of the presence of PMA or 4-MU.
36766693	6	37	gly	fibrinogen	1460:1469	arg1	increasingly exposed mannose residues	fibrinogen			increasingly exposed mannose residues	PUBTATOR		fibrinogen	2244		Since patients with ESRD are prone to cardiovascular complications and the formation of atherosclerotic plaques, one can hypothesize that fibrinogen with increasingly exposed mannose residues may contribute to the unwanted events.
36377874	1	72	gly	protein	150:156	arg1	The glycan loop	envelope protein			The glycan loop	PUBTATOR		envelope protein	64006		The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36924942	4	84	gly	3-deoxy-β-d-manno-oct-2-ulosonic	593:624	arg1	β-Kdo	oct-2			β-Kdo	OGER		oct-2	P09086		Two separate GT modules in KpsC transfer 3-deoxy-β-d-manno-oct-2-ulosonic acid (β-Kdo) from cytidine-5'-monophospho-β-Kdo donor, to a glycolipid acceptor.
36565355	8	44	gly	glycosylation	875:887	arg1	the NOTCH1 signaling pathway	the NOTCH1 signaling pathway				PUBTATOR		NOTCH1	18128		To investigate the role of glycosylation in the NOTCH1 signaling pathway, nuclear magnetic resonance spectroscopy has been employed to study the structures of EGF27 and its glycoforms.
35713525	5	36	gly	attached	606:613	arg1	Sur1 AND N-glycans	Sur1			N-glycans	PUBTATOR		Sur1	856050		In this study, we elucidated the roles played by N-glycans attached to Sur1 and Csh1, and dissected the mechanisms underlying substrate recognition by these 2 enzymes.
35713525	5	36	gly	attached	606:613	arg1	Csh1 AND N-glycans	Csh1			N-glycans	PUBTATOR		Csh1	852458		In this study, we elucidated the roles played by N-glycans attached to Sur1 and Csh1, and dissected the mechanisms underlying substrate recognition by these 2 enzymes.
36797772	3	80	gly	FAS1	514:517	arg1	N-linked glycans	FAS1			N-linked glycans	OGER		FAS1	P25445		FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36189205	4	2	gly	FcγRIIIa	813:820	arg1	different N-glycan structures	FcγRIIIa			different N-glycan structures	PUBTATOR		FcγRIIIa	2214		In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
36189205	4	9	gly	IgG1	804:807	arg1	different N-glycan structures	IgG1			different N-glycan structures	OGER		IgG1	P01857		In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
37121976	5	1	gly	deglycosylation	884:898	arg1	LRG1	LRG1				OGER		LRG1	P02750		In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
33727825	1	16	gly	glycoprotein	159:170	arg1	BACKGROUND Ribophorin II	BACKGROUND Ribophorin II				PUBTATOR		Ribophorin II	6185		BACKGROUND Ribophorin II (RPN2) is a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins.
36029899	9	14	gly	N-glycosylation	1338:1352	arg1	an active ADA2 enzyme	an active ADA2 enzyme				PUBTATOR		ADA2 enzyme	51816		CONCLUSIONS These data suggest that the initial N-glycosylation and N-glycan editing in the ER are essential for the production of an active ADA2 enzyme and proper trafficking to the extracellular space.
35577189	7	27	gly	cAMPF	1280:1284	arg1	a functional edible polysaccharide film	cAMPF			a functional edible polysaccharide film	Cterm		cAMPF	P49913		All these data suggested the potential value of cAMPF as a functional edible polysaccharide film applied in food industries.
36598201	7	109	gly	N-glycosylation	1101:1115	arg1	NSP4	NSP4				OGER		NSP4	Q14B24		Specifically, replications of glycosylation-defective virus in MA104 and HT29 cells were 10- and 100,000-fold lower, respectively, than that of the wild-type, suggesting that N-glycosylation of NSP4 plays a critical role in RV replication.
32791164	11	51	gly	carrying	1847:1854	arg1	DMBT1 AND O-linked sialylated keratan sulfate chains	DMBT1			O-linked sialylated keratan sulfate chains	OGER		isoform of DMBT1	Q9UGM3		Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
35616904	7	33	gly	detected	1020:1027	arg2	galectin-3-binding protein AND heavy fucosylation	galectin-3-binding protein			heavy fucosylation	PUBTATOR		galectin-3-binding protein	3959		As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	33	gly	detected	1020:1027	arg1	clusterin AND heavy fucosylation	clusterin			heavy fucosylation	OGER		clusterin	P10909		As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	70	gly	fucosylation	966:977	arg1	galectin-3-binding protein	galectin-3-binding protein				PUBTATOR		galectin-3-binding protein	3959		As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	70	gly	fucosylation	966:977	arg1	clusterin	clusterin				OGER		clusterin	P10909		As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	71	gly	glycoproteins	1047:1059	arg1	galectin-3-binding protein	galectin-3-binding protein				PUBTATOR		galectin-3-binding protein	3959		As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	71	gly	glycoproteins	1047:1059	arg1	clusterin	clusterin				OGER		clusterin	P10909		As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
36409896	4	10	gly	glycoforms	630:639	arg1	IgG	IgG				Cterm		IgG			We apply this technology to immunoglobulin G (IgG) Fc glycoforms and define nanobodies that specifically recognize either IgG lacking its core-fucose or IgG bearing terminal sialic acid residues.
36409896	4	10	gly	glycoforms	630:639	arg1	immunoglobulin G	immunoglobulin G				Cterm		immunoglobulin G			We apply this technology to immunoglobulin G (IgG) Fc glycoforms and define nanobodies that specifically recognize either IgG lacking its core-fucose or IgG bearing terminal sialic acid residues.
35504880	3	48	gly	GT-A	506:509	arg1	C1GalT1	GT-A			C1GalT1	PUBTATOR		GT-A	3674		Through biophysical and cellular studies, including X-ray crystallography of C1GalT1 complexed to a glycopeptide, we report that C1GalT1 is an obligate GT-A fold dimer that follows a SN2 mechanism.
36036581	3	16	gly	N-glycosylation	380:394	arg1	the S protein	the S protein				PUBTATOR		S protein	7448		Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
37173020	5	25	gly	TLR4	956:959	arg1	leucine-rich repeats	TLR4			leucine-rich repeats	OGER		TLR4	O00206		Via structural investigation, the inner concavity of leucine-rich repeats of TLR4 was predicted to act as a binding motif for carbohydrate recognition, and subsequent simulations predicted the binding modes and conformations.
36791651	2	37	gly	CFF	458:460	arg1	polysaccharides	CFF			polysaccharides	OGER		CFF	P51610		Phytochemical studies found that phenylpropanoids, flavonoids, terpenoids and polysaccharides were the main ingredients of CFF.
32796070	2	55	gly	glycoprotein	336:347	arg1	the viral Env glycoprotein gp120	the viral Env glycoprotein gp120				PUBTATOR		Env glycoprotein	100616444		HIV-1 susceptibility to SERINC5 is determined by sequences in the viral Env glycoprotein gp120, and the antiviral effect of SERINC5 is counteracted by the viral accessory protein Nef.
36409896	0	4	gly	glycoforms	52:61	arg1	IgG Fc glycoforms	IgG Fc glycoforms				Cterm		IgG			Synthetic nanobodies as tools to distinguish IgG Fc glycoforms.
33199824	9	40	gly	modification	1104:1115	arg1	SMAD4 Thr63	SMAD4			modification	PUBTATOR		SMAD4	4089		In addition, O-GlcNAc modification on SMAD4 Thr63 was responsible for stabilization.
35995381	12	69	gly	N-glycosylation	1837:1851	arg1	human thyroid thyroglobulin protein	human thyroid thyroglobulin protein				OGER		thyroglobulin protein	P01266		The present research significantly expanded the knowledge regarding N-glycosylation profiles of human thyroid thyroglobulin protein.
35622127	0	91	gly	N-glycosylation	50:64	arg1	IgG	IgG				Cterm		IgG			Children at onset of type 1 diabetes show altered N-glycosylation of plasma proteins and IgG.
36447399	5	71	gly	have	1088:1091	arg1	human IgG1 AND a Fab glycan	human IgG1			a Fab glycan	OGER		IgG1	P01857		Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
35470665	1	0	gly	glycosylation	93:105	arg1	HIV-1	HIV-1				PUBTATOR		HIV-1) envelope protein	64006		Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35279850	7	94	gly	found	1277:1281	arg2	DPM3- AND group-specific high-mannose N-glycan signatures	DPM3-			group-specific high-mannose N-glycan signatures	OGER		DPM3	Q9P2X0		Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	gly	found	1277:1281	arg2	ALG11- AND group-specific high-mannose N-glycan signatures	ALG11-			group-specific high-mannose N-glycan signatures	OGER		ALG11	Q2TAA5		Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	gly	found	1277:1281	arg2	MPDU1- AND group-specific high-mannose N-glycan signatures	MPDU1-			group-specific high-mannose N-glycan signatures	OGER		MPDU1	O75352		Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	gly	found	1277:1281	arg2	ALG12- AND group-specific high-mannose N-glycan signatures	ALG12-			group-specific high-mannose N-glycan signatures	OGER		ALG12	Q9BV10		Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	gly	found	1277:1281	arg2	DOLK- AND group-specific high-mannose N-glycan signatures	DOLK-			group-specific high-mannose N-glycan signatures	OGER		DOLK	Q9UPQ8		Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	gly	found	1277:1281	arg1	ALG3- AND group-specific high-mannose N-glycan signatures	ALG3-			group-specific high-mannose N-glycan signatures	OGER		ALG3	Q92685		Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	gly	found	1277:1281	arg1	DPM1- AND group-specific high-mannose N-glycan signatures	DPM1-			group-specific high-mannose N-glycan signatures	OGER		DPM1	O60762		Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	gly	found	1277:1281	arg1	ALG13-CDG AND group-specific high-mannose N-glycan signatures	ALG13-CDG			group-specific high-mannose N-glycan signatures	OGER		ALG13	Q9NP73		Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	gly	found	1277:1281	arg1	ALG9- AND group-specific high-mannose N-glycan signatures	ALG9-			group-specific high-mannose N-glycan signatures	OGER		ALG9	Q9H6U8		Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	gly	found	1277:1281	arg1	RFT1- AND group-specific high-mannose N-glycan signatures	RFT1-			group-specific high-mannose N-glycan signatures	OGER		RFT1	Q9NWF4		Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	gly	found	1277:1281	arg1	SRD5A3- AND group-specific high-mannose N-glycan signatures	SRD5A3-			group-specific high-mannose N-glycan signatures	OGER		SRD5A3	Q9H8P0		Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
36535347	5	35	gly	SRP	772:774	arg1	The carbohydrate content	SRP			The carbohydrate content	OGER		SRP	Q96RP3		The carbohydrate content of SRP was 85.09 %, with a relatively high content of uronic acids (11.27 %).
32494619	4	8	gly	IRF5	648:651	arg1	O-GlcNAcylation	IRF5			O-GlcNAcylation	OGER		IRF5	Q13568		O-GlcNAcylation of IRF5 is required for K63-linked ubiquitination of IRF5 and subsequent cytokine production.
36007953	1	19	gly	N-glycosylated	214:227	arg1	S protein	S protein				OGER		S protein	Q15517		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
33609912	6	61	gly	deglycosylated	982:995	arg1	purified IgG1 and neutralizing IgG1	purified IgG1 and neutralizing IgG1				OGER		IgG1	P01857		The activity of purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme were analyzed using the rapid fluorescent focus inhibition test.
37202422	4	33	gly	glycoforms	591:600	arg1	IgG glycoforms	IgG glycoforms				Cterm		IgG			We previously reported synthetic nanobodies that distinguish IgG glycoforms.
37366623	9	8	gly	glycoprotein	1738:1749	arg1	the envelope glycoprotein B	the envelope glycoprotein B				Cterm		the envelope glycoprotein B (gB			Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
33609912	11	86	gly	deglycosylated	1767:1780	arg1	the deglycosylated IgG1	the deglycosylated IgG1				OGER		IgG1	P01857		Different glycosylation profiles were also observed in Fab and Fc fragments from neutralizing and non-neutralizing IgG1, although the deglycosylated IgG1 lost its neutralizing activity.
37294165	4	67	gly	N-glycosylated	685:698	arg1	SPINK13	N-glycosylated form of SPINK13				OGER		N-glycosylated form of SPINK13	Q1W4C9		Herein we report the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method.
34689907	8	67	gly	glycoprotein	1610:1621	arg1	Human Immunoglobulin G	Human Immunoglobulin G				Cterm		Human Immunoglobulin G			The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34611869	7	28	gly	glycosylated	1283:1294	arg1	the glycosylated asparagine side chains	the glycosylated asparagine side chains				OGER		chains			Therefore, in these structures we modified the Fc glycan regions by adjusting the glycosylated asparagine side chains and glycosidic bonds.
34957216	1	65	gly	glycoprotein	308:319	arg1	S	S				PUBTATOR		S	43740568		Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
36914840	7	51	gly	glycoforms	1431:1440	arg1	the IgG3-G2 and S1 glycoforms	the IgG3-G2 and S1 glycoforms				OGER		IgG3	P01860		However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
34735575	4	49	gly	glycosylation	1053:1065	arg1	similarly produced spike proteins	similarly produced spike proteins				PUBTATOR		spike proteins	43740568		Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
33583770	10	28	gly	N-glycosylation	2006:2020	arg1	galectin-1	galectin-1				PUBTATOR		galectin-1	16852		Importantly, similar changes in N-glycosylation and the upregulation of galectin-1 during postnatal skeletal muscle development were observed in mice.
32839225	6	4	gly	sialoglycopeptides	969:986	arg1	EL	EL				Cterm		EL	16891		As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	4	gly	sialoglycopeptides	969:986	arg1	C4b-binding protein	C4b-binding protein				PUBTATOR		C4b-binding protein	12269		As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	4	gly	sialoglycopeptides	969:986	arg1	testis-expressed protein 101	testis-expressed protein 101				PUBTATOR		52, testis-expressed protein 101	56746		As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	4	gly	sialoglycopeptides	969:986	arg1	endothelial lipase	endothelial lipase				PUBTATOR		endothelial lipase	16891		As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	4	gly	sialoglycopeptides	969:986	arg1	zonadhesin	zonadhesin				PUBTATOR		zonadhesin	Q9Y493		As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
35370997	1	28	gly	glycoprotein	253:264	arg1	immunoglobulin G	immunoglobulin G				Cterm		immunoglobulin G			The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum, reflects pathological conditions of autoimmunity and is sensitive to medicines applied in disease therapy.
35945033	7	10	gly	glycoproteins	1678:1690	arg1	bovine lactoferrin	bovine lactoferrin				OGER		lactoferrin	P02788		Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	7	16	gly	deglycosylate	1660:1672	arg1	bovine lactoferrin	bovine lactoferrin				OGER		lactoferrin	P02788		Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
33316265	2	33	gly	modification	334:345	arg3	eNOS AND O-GlcNAc modification	eNOS			O-GlcNAc modification	PUBTATOR		eNOS	24600		MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	33	gly	modification	334:345	arg3	endothelial nitric oxide synthase AND O-GlcNAc modification	endothelial nitric oxide synthase			O-GlcNAc modification	PUBTATOR		endothelial nitric oxide synthase	24600		MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	43	gly	synthase	375:382	arg1	MAIN METHODS O-GlcNAc levels	endothelial nitric oxide synthase			MAIN METHODS O-GlcNAc levels	PUBTATOR		endothelial nitric oxide synthase	24600		MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	43	gly	synthase	375:382	arg1	O-GlcNAc modification	endothelial nitric oxide synthase			O-GlcNAc modification	PUBTATOR		endothelial nitric oxide synthase	24600		MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
35651042	4	36	gly	TFP	601:603	arg1	constituent monosaccharide	TFP			constituent monosaccharide	OGER		TFP	Q9HCM9		The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	4	36	gly	TFP	601:603	arg1	the reducing sugar content	TFP			the reducing sugar content	OGER		TFP	Q9HCM9		The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
36606688	5	52	gly	structure	627:635	arg1	SOD3	SOD3			structure	PUBTATOR		SOD3	6649		We report herein that the fucose structure of the N-glycan in SOD3 was increased in the sera of patients with lung cancer.
36014516	4	75	gly	SPs	886:888	arg1	the polysaccharide fragment Mn	SPs			the polysaccharide fragment Mn	OGER		SPs	P49903		Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	75	gly	SPs	886:888	arg1	Two monosaccharides	SPs			Two monosaccharides	OGER		SPs	P49903		Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
34695439	0	51	gly	glycosylation	47:59	arg1	TSP1	TSP1				PUBTATOR		TSP1	7057		Loss of the AMD-associated B3GLCT gene affects glycosylation of TSP1 without impairing secretion in retinal pigment epithelial cells.
37037133	3	36	gly	glycoproteins	520:532	arg1	donkey and human MFGM glycoproteins	donkey and human MFGM glycoproteins				OGER		MFGM glycoproteins	Q08431		This study aimed to map the most comprehensive site-specific N-glycosylation fingerprinting of donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy.
35995381	11	45	gly	N-glycosylation	1648:1662	arg1	human thyroglobulin	human thyroglobulin				PUBTATOR		thyroglobulin	7038		Therefore, a comprehensive analysis of the N-glycosylation sites of human thyroglobulin is essential to improve our understanding of the function of its N-glycans.
34939096	4	24	gly	mAbs	1122:1125	arg1	sialylation	IgG4 mAbs			sialylation	OGER		IgG4 mAbs	P01861		Scalability of the reactions was demonstrated for mAb amounts ranging from 1 mg to 1 g. Additionally, the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase were shown to work on column during affinity chromatography using Protein A or KappaSelect, the latter providing more efficient galactosylation and sialylation of IgG1 and IgG4 mAbs.
34939096	4	83	gly	sialylation	1093:1103	arg1	IgG1 and IgG4 mAbs	IgG1 and IgG4 mAbs				OGER		IgG4 mAbs	P01861		Scalability of the reactions was demonstrated for mAb amounts ranging from 1 mg to 1 g. Additionally, the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase were shown to work on column during affinity chromatography using Protein A or KappaSelect, the latter providing more efficient galactosylation and sialylation of IgG1 and IgG4 mAbs.
36029899	4	73	gly	N-glycosylation	504:518	arg1	ADA2	ADA2				PUBTATOR		ADA2	51816		METHODS We investigated the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2 via site-directed mutagenesis and the application of N-glycosylation inhibitors.
35335137	9	24	gly	structures	1084:1093	arg1	unilateral AMD	AMD			structures	OGER		AMD	P17707		Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
36754227	3	14	gly	N-glycan	426:433	arg1	SV2C	SV2C			N-glycan	OGER		SV2C	Q496J9		Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
34878920	1	7	gly	glycoprotein	115:126	arg1	Env	Env				PUBTATOR		Env	64006		Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	1	7	gly	glycoprotein	115:126	arg1	envelope glycoprotein	envelope glycoprotein				PUBTATOR		envelope glycoprotein	64006		Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	1	85	gly	Glycans	95:101	arg1	Env	Env			Glycans	PUBTATOR		Env	64006		Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	1	85	gly	Glycans	95:101	arg1	envelope glycoprotein	envelope glycoprotein			Glycans	PUBTATOR		envelope glycoprotein	64006		Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
36892535	8	34	gly	linked	1258:1263	arg1	MUC1 AND glycans	MUC1			glycans	OGER		MUC1	P15941		These experiments revealed only minor differences in peptide structure, therefore clearly relating the adhesion behaviour to the type and number of glycans linked to MUC1.
36288283	6	28	gly	GPC	1005:1007	arg1	the extensive glycan shield	GPC			the extensive glycan shield	OGER		GPC	P04921		These antibodies either circumvent or exploit specific glycans comprising the extensive glycan shield of GPC.
32531122	0	40	gly	N-glycosylated	0:13	arg1	N-glycosylated IgG	N-glycosylated IgG				Cterm		IgG			N-glycosylated IgG in patients with kidney transplants increases calcium/calmodulin kinase IV in podocytes and causes injury.
36746580	5	54	gly	glycoproteins	923:935	arg1	human MFGM glycoproteins	MFGM glycoproteins			Lewis	OGER		MFGM glycoproteins	Q08431		Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	5	54	gly	glycoproteins	923:935	arg1	human MFGM glycoproteins	MFGM glycoproteins			core-α1,6-fucosylated structures	OGER		MFGM glycoproteins	Q08431		Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	5	54	gly	glycoproteins	923:935	arg1	human MFGM glycoproteins	MFGM glycoproteins			sialylated branching structures	OGER		MFGM glycoproteins	Q08431		Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36606688	4	57	gly	N-glycosylation	437:451	arg1	SOD3	SOD3				PUBTATOR		SOD3	6649		Although we reported previously that the N-glycosylation of SOD3 was essential for its secretion, the role played by the N-glycosylation of SOD3, as it relates to lung cancer, is poorly understood.
36606688	4	66	gly	N-glycosylation	517:531	arg1	SOD3	SOD3				PUBTATOR		SOD3	6649		Although we reported previously that the N-glycosylation of SOD3 was essential for its secretion, the role played by the N-glycosylation of SOD3, as it relates to lung cancer, is poorly understood.
36606688	3	29	gly	contains	362:369	arg1	SOD3 AND a single N-glycan chain	SOD3			a single N-glycan chain	PUBTATOR		SOD3	6649		SOD3 is an extracellular superoxide dismutase and contains a single N-glycan chain.
36131913	8	44	gly	glycans	1547:1553	arg1	Asn162			Asn162	Asn162		AminoAcid			Asn45 and Asn162, Val158	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36131913	8	44	gly	glycans	1547:1553	arg1	Asn45			Asn45	Asn45		AminoAcid			Asn45 and Asn162, Val158	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36329887	12	34	gly	glycoforms	2283:2292	arg1	different FSH glycoforms	different FSH glycoforms				OGER		FSH			Accordingly, the differences in binding capacity of the same receptor preparation to different FSH glycoforms are likely the organization of the FSH receptor in cell membranes, rather than the αAsn<sup>52</sup> oligosaccharide.
36095053	2	46	gly	glycosylated	288:299	arg1	TREM2	TREM2				PUBTATOR		TREM2	54209		TREM2 is glycosylated in vitro and in vivo, but the significance of the modification is unknown.
33078708	3	8	gly	glycosylated	511:522	arg1	CatSper1	CatSper1				OGER		CatSper1	Q8NEC5		Here using biochemical and pharmacological studies, we demonstrate that CatSper1 is an O-linked glycosylated protein, undergoing capacitation-induced processing dependent on Ca2+ and phosphorylation cascades.
35279850	2	39	gly	N-glycans	403:411	arg1	transferrin	transferrin			N-glycans	OGER		transferrin	P02787		The biochemical hallmark of CDG-I is a partial absence of complete N-glycans on transferrin.
35507105	8	63	gly	glycoforms	1607:1616	arg1	insulin glycoforms	insulin glycoforms				PUBTATOR		insulin	3630		This work helps better explain how O-linked glycosylation influences the proteolytic stability and monomeric propensity of insulin, illuminating a path towards rational molecular design of insulin glycoforms.
36698045	4	30	gly	N-glycosylated	559:572	arg1	the spike	the spike				PUBTATOR		spike	43740568		As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36534501	6	11	gly	lumican	1043:1049	arg1	glycan chains	lumican			glycan chains	PUBTATOR		lumican	4060		The impact of the number of glycan chains, structures, and dynamics of lumican on the interaction with MMP-14 was assessed by molecular dynamics simulations.
36809652	2	32	gly	galectin-1	357:366	arg1	The O-glycan structures	galectin-1			The O-glycan structures	OGER		galectin-1	P09382		The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
35715659	3	7	part_of	NSRC	546:549	arg1	NCI-N87	NSRC		NCI-N87		Cterm	SpecificSite	NSRC	6714	N87	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	11	part_of	non-SRC	537:543	arg1	NCI-N87	SRC		NCI-N87		PUBTATOR	SpecificSite	SRC	6714	N87	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35670884	4	41	gly	contains	728:735	arg1	SPARC AND a core-fucosylation site	SPARC			a core-fucosylation site	PUBTATOR		SPARC	6678		Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
36189205	3	22	gly	N-glycosylation	450:464	arg1	the FcγRIII	the FcγRIII				PUBTATOR		FcγRIII	2214		Studies have suggested that also N-glycosylation of the FcγRIII affects receptor interactions with IgG, but detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans have been hindered by the natural heterogeneity in N-glycosylation.
34650217	8	23	gly	KAT5	1288:1291	arg1	targeting HBP-mediated O-GlcNAcylation	KAT5			targeting HBP-mediated O-GlcNAcylation	OGER		KAT5	Q8CHK4		In addition, targeting HBP-mediated O-GlcNAcylation of KAT5 inhibits lung metastasis of HCC in hepatospecific Pck1-deletion mice.
33515675	10	1	gly	NOTCH1	1410:1415	arg1	the O-GlcNAcylation	NOTCH1			the O-GlcNAcylation	PUBTATOR		NOTCH1	18128		We further clarified the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.
32636304	1	18	gly	found	279:283	arg2	the surface envelope glycoprotein-120 (gp120) AND the high-mannose glycans	the surface envelope glycoprotein-120 (gp120)			the high-mannose glycans	OGER		gp120	Q14624		N-Linked glycans are critical to the infection cycle of HIV, and most neutralizing antibodies target the high-mannose glycans found on the surface envelope glycoprotein-120 (gp120).
36637420	7	10	gly	non-glycosylated	1335:1350	arg1	non-glycosylated HAI-2	non-glycosylated HAI-2				PUBTATOR		HAI-2	10653		Unexpectedly, the vast majority of non-glycosylated HAI-2 is synthesized into multiple disulfide-linked oligomers, which lack protease inhibitory function, likely due to distorted conformations caused by the disarrayed disulfide linkages.
36809652	4	26	gly	galectin-1	592:601	arg1	Carbohydrate-dependent binding	galectin-1			Carbohydrate-dependent binding	OGER		galectin-1	P09382		Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	4	95	gly	O-glycoprotein	614:627	arg1	neuropilin-1	neuropilin-1				OGER		neuropilin-1	O14786		Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36036581	2	42	gly	protein	329:335	arg1	site-specific glycan compositions	S protein			site-specific glycan compositions	PUBTATOR		S protein	7448		Previous studies have systematically analyzed site-specific glycan compositions as well as many important structural motifs of the S protein.
36235191	6	58	gly	DDO	1465:1467	arg1	three polysaccharide fragments	DDO			three polysaccharide fragments	OGER		DDO	Q99489		The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	6	59	gly	fragments	1417:1425	arg1	the DDO	DDO			fragments	OGER		DDO	Q99489		The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36746580	7	28	gly	glycoproteins	1299:1311	arg1	human MFGM glycoproteins	human MFGM glycoproteins				OGER		MFGM glycoproteins	Q08431		Meanwhile, the study deepens our understanding of site-specific N-glycosylation of human MFGM glycoproteins.
36746580	7	47	gly	N-glycosylation	1269:1283	arg1	human MFGM glycoproteins	human MFGM glycoproteins				OGER		MFGM glycoproteins	Q08431		Meanwhile, the study deepens our understanding of site-specific N-glycosylation of human MFGM glycoproteins.
37348475	5	22	gly	SPO-AGP	946:952	arg1	the glycan structures	SPO			the glycan structures	OGER		SPO	P22079		Comparison of the glycan structures of the microsomal SPO-AGP and the secreted SPO-AGPΔC using antibodies against the glycan epitopes of AGP indicated that the glycan structures of these proteins are different.
37348475	5	54	gly	AGP	1029:1031	arg1	the glycan epitopes	AGP			the glycan epitopes	Cterm		AGP			Comparison of the glycan structures of the microsomal SPO-AGP and the secreted SPO-AGPΔC using antibodies against the glycan epitopes of AGP indicated that the glycan structures of these proteins are different.
36813234	8	64	gly	contains	1455:1462	arg1	TNFR2 AND bisected N-glycans	TNFR2			bisected N-glycans	OGER		TNFR2	P20333		Interestingly, our immunoprecipitation analysis revealed that only TNFR2, but not TNFR1, contains bisected N-glycans.
36813234	8	64	gly	contains	1455:1462	arg1	TNFR1 AND bisected N-glycans	TNFR1			bisected N-glycans	OGER		TNFR1	P19438		Interestingly, our immunoprecipitation analysis revealed that only TNFR2, but not TNFR1, contains bisected N-glycans.
32149134	1	16	gly	glycoprotein	145:156	arg1	PURPOSE CD147	PURPOSE CD147				PUBTATOR		|PURPOSE
CD147|	682		PURPOSE CD147, also known as BSG, is a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily.
32149134	2	29	gly	glycosylated	231:242	arg1	Mature CD147	Mature CD147				PUBTATOR		Mature CD147	682		Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors.
36409896	6	41	gly	glycoforms	1188:1197	arg1	IgG Fc glycoforms	IgG Fc glycoforms				Cterm		IgG			Ultimately, we provide a strategy for the development of reagents to identify and manipulate IgG Fc glycoforms.
32417172	8	89	gly	glycosylated	1265:1276	arg1	The p53	The p53				OGER		p53	P04637		RESULTS The p53 was O-GalNAc glycosylated in cells.
32130226	5	11	gly	glycosylated	947:958	arg1	vitellogenin VIT-6	vitellogenin VIT-6				OGER		VIT	Q6UXI7		We identified vitellogenin VIT-6 as an OST-dependent glycosylated protein, critical for maintaining survival on PA14.
35307819	5	61	gly	IgGs	818:821	arg1	the glycans composition	IgGs			the glycans composition	Cterm		IgGs	668542		We found that SARS-CoV-2+ individuals display, at diagnosis, variations in the glycans composition of circulating IgGs.
36598201	0	101	gly	N-Glycosylation	0:14	arg1	Rotavirus NSP4 Protein	Rotavirus NSP4 Protein				OGER		Rotavirus NSP4 Protein	Q14B24		N-Glycosylation of Rotavirus NSP4 Protein Affects Viral Replication and Pathogenesis.
35751935	7	27	gly	contained	1037:1045	arg1	The LMP AND arabinose	The LMP			arabinose	OGER		LMP			The LMP extracted by EADU contained arabinose, galactose, and glucose in the molar ratios of 2.9:2.72:5.05.
35751935	7	27	gly	contained	1037:1045	arg1	The LMP AND galactose	The LMP			galactose	OGER		LMP			The LMP extracted by EADU contained arabinose, galactose, and glucose in the molar ratios of 2.9:2.72:5.05.
35751935	7	27	gly	contained	1037:1045	arg1	The LMP AND glucose	The LMP			glucose	OGER		LMP			The LMP extracted by EADU contained arabinose, galactose, and glucose in the molar ratios of 2.9:2.72:5.05.
35311852	9	87	gly	glycoproteins	1365:1377	arg1	κ-casein	κ-casein				PUBTATOR		-casein	281728		Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	9	87	gly	glycoproteins	1365:1377	arg1	ribonuclease B	ribonuclease B				Cterm		ribonuclease B			Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	9	97	gly	derived	1346:1352	arg1	ribonuclease B AND N- and O-glycan isomers	ribonuclease B			N- and O-glycan isomers	Cterm		ribonuclease B			Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	9	97	gly	derived	1346:1352	arg1	κ-casein AND N- and O-glycan isomers	κ-casein			N- and O-glycan isomers	PUBTATOR		-casein	281728		Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
36746580	3	20	gly	glycoproteins	546:558	arg1	221 MFGM glycoproteins	221 MFGM glycoproteins			986 unique site-specific N-glycans	OGER		221 MFGM glycoproteins	Q08431		Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	3	20	gly	glycoproteins	546:558	arg1	221 MFGM glycoproteins	221 MFGM glycoproteins			2617 unique site-specific N-glycans	OGER		221 MFGM glycoproteins	Q08431		Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	3	16	gly	glycoproteins	630:642	arg1	986 unique site-specific N-glycans	200 MFGM glycoproteins			986 unique site-specific N-glycans	OGER		200 MFGM glycoproteins	Q08431		Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	3	16	gly	glycoproteins	630:642	arg1	2617 unique site-specific N-glycans	200 MFGM glycoproteins			2617 unique site-specific N-glycans	OGER		200 MFGM glycoproteins	Q08431		Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36239409	5	72	gly	K84	1401:1403	arg1	capsular polysaccharides	K84			capsular polysaccharides	OGER		K84	Q9NSB2		The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
34878920	0	88	gly	Glycosylation	0:12	arg1	ALV-J Envelope Protein	ALV-J Envelope Protein				PUBTATOR		ALV-J Envelope Protein	64006		Glycosylation of ALV-J Envelope Protein at Sites 17 and 193 Is Pivotal in the Virus Infection.
37266972	10	17	gly	glycoprotein	1258:1269	arg1	glycoprotein B	glycoprotein B				Cterm		glycoprotein B			Likewise, extensive deglycosylation of glycoprotein B, which possesses 18 N-glycosylation sites, was observed.
37266972	10	20	gly	deglycosylation	1239:1253	arg1	glycoprotein B	glycoprotein B				Cterm		glycoprotein B			Likewise, extensive deglycosylation of glycoprotein B, which possesses 18 N-glycosylation sites, was observed.
36746580	2	85	gly	N-glycosylation	350:364	arg1	human MFGM proteins	human MFGM proteins				OGER		MFGM proteins	Q08431		However, the profiles and landscape changes in the site-specific N-glycosylation of human MFGM proteins during lactation remain unclear.
36809652	1	85	gly	O-glycoprotein	209:222	arg1	Apolipoprotein(a) [apo	Apolipoprotein(a) [apo				OGER		apo(a	P08519		Apolipoprotein(a) [apo(a)] is a highly polymorphic O-glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)].
37189353	0	45	gly	N-Glycosylation	4:18	arg1	IgG	IgG				Cterm		IgG			The N-Glycosylation of Total Plasma Proteins and IgG in Atrial Fibrillation.
37294165	3	13	gly	glycosylated	528:539	arg1	glycosylated SPINK 13	glycosylated SPINK 13				OGER		SPINK 13	Q1W4C9		In addition to this, the preparation of glycosylated SPINK 13 has not been examined by both the cell expression method and chemical synthesis.
36598201	11	39	gly	N-glycosylation	1735:1749	arg1	NSP4	NSP4				OGER		NSP4	Q14B24		Taken together, the data suggest that N-glycosylation of NSP4 plays a vital role in viral replication and pathogenicity.
36029899	6	25	gly	N-glycosylation	839:853	arg1	ADA2	ADA2				PUBTATOR		ADA2	51816		RESULTS Inhibiting the initial N-glycosylation of ADA2 in the ER via site-directed mutagenesis or treatment with N-glycosylation inhibitors reduced the intracellular ADA2 activity and secretion.
34695439	5	87	gly	glycosylation	799:811	arg1	thrombospondin 1	thrombospondin 1				PUBTATOR		thrombospondin 1	7057		We generated B3GLCT knockout (KO) RPE cells and analyzed glycosylation and secretion of thrombospondin 1 (TSP1), a protein involved in cellular processes highly relevant to AMD.
34695439	5	87	gly	glycosylation	799:811	arg1	TSP1	TSP1				PUBTATOR		TSP1	7057		We generated B3GLCT knockout (KO) RPE cells and analyzed glycosylation and secretion of thrombospondin 1 (TSP1), a protein involved in cellular processes highly relevant to AMD.
36493594	6	38	gly	N-glycans	1109:1117	arg1	IgG	IgG			N-glycans	Cterm		IgG			The N-glycans in fetuin (8-13 N-glycans were previously reported) and in IgG (19 N-glycans were previously reported), which could not be identified by using the widely used PF-AB, were all identified by using PF-ProA or PA-ProA.
32417172	0	55	gly	present	47:53	arg2	the tumor suppressor p53 AND O-linked N-acetylgalactosamine modification	tumor suppressor p53			O-linked N-acetylgalactosamine modification	OGER		tumor suppressor p53	P04637		O-linked N-acetylgalactosamine modification is present on the tumor suppressor p53.
37366623	0	38	gly	glycoprotein	48:59	arg1	the envelope glycoprotein B	the envelope glycoprotein B				Cterm		the envelope glycoprotein B			Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
31901900	3	36	gly	PD-L1	724:728	arg1	N-linked glycan decoration	PD-L1			N-linked glycan decoration	PUBTATOR		PD-L1	29126		Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
36637420	4	0	gly	matriptase	864:873	arg1	complex-type	matriptase			complex-type	OGER		matriptase	P56677		HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	4	3	gly	prostasin	879:887	arg1	complex-type	prostasin			complex-type	PUBTATOR		prostasin	5652		HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
33904933	0	30	gly	antigen	48:54	arg1	annexin A2 protein	annexin A2 protein			antigen	PUBTATOR		annexin A2 protein	302		Human colorectal cancer-associated carbohydrate antigen on annexin A2 protein.
35276597	0	45	gly	N-glycosylation	30:44	arg1	plant-derived native and recombinant miraculin	plant-derived native and recombinant miraculin				PUBTATOR		miraculin	101255468		Effect of fruit maturation on N-glycosylation of plant-derived native and recombinant miraculin.
32365408	8	8	gly	OGT	1375:1377	arg1	5SGlcNHex	OGT			5SGlcNHex	OGER		OGT	Q8CGY8		Moreover, treatment of cells with the OGT inhibitor, 5SGlcNHex, increases the level of uptake of α-syn PFFs, further supporting O-GlcNAcylation of proteins driving these effects.
36377874	0	13	gly	Deletions	69:77	arg1	the Envelope Protein	Envelope Protein			Deletions	PUBTATOR		Envelope Protein	64006		Pathogenicity and Structural Basis of Zika Variants with Glycan Loop Deletions in the Envelope Protein.
35364207	0	61	gly	glycosylation	35:47	arg1	lactoferrin	lactoferrin				OGER		lactoferrin	P02788		Effect of chitosan oligosaccharide glycosylation on the emulsifying property of lactoferrin.
37266972	6	18	gly	glycoprotein	823:834	arg1	glycoprotein B	glycoprotein B				Cterm		glycoprotein B			To this end, endoglycosidase T was co-expressed with an immunoglobulin G or glycoprotein B of human cytomegalovirus in BY-2 cell lines producing only high mannose N-glycans.
35320529	6	10	gly	structures	988:997	arg1	CD16a	CD16a			structures	PUBTATOR		CD16a	2214		Donor-dependent variability in N-glycan structures on CD16a isolated from primary NK cells of healthy human donors was recently reported.
36014368	0	61	gly	N-Glycosylation	21:35	arg1	the SARS-CoV-2 S Protein	the SARS-CoV-2 S Protein				PUBTATOR		S Protein	7448		Investigation of the N-Glycosylation of the SARS-CoV-2 S Protein Contained in VLPs Produced in Nicotiana benthamiana.
36493594	3	75	gly	glycoproteins	697:709	arg1	human IgG	human IgG				Cterm		IgG			METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
35397991	3	44	gly	GNTI	509:512	arg1	the resultant N-glycan structures	GNTI			the resultant N-glycan structures	OGER		GNTI	P26572		However, the temporal contributions of GNTI to GlcNAc extension and the resultant N-glycan structures in insects have not been analyzed.
35604098	3	46	gly	glycosylated	544:555	arg1	cholera toxin B-subunit	cholera toxin B-subunit				PUBTATOR		cholera toxin B-subunit	9468		In this work, we designed and synthesized an intentionally glycosylated cholera toxin B-subunit (CTB) to be transported to the organelles of mammalian cells.
35604098	3	46	gly	glycosylated	544:555	arg1	CTB	CTB				PUBTATOR		CTB	9468		In this work, we designed and synthesized an intentionally glycosylated cholera toxin B-subunit (CTB) to be transported to the organelles of mammalian cells.
37121976	4	8	gly	N-glycosylation	788:802	arg1	LRG1	LRG1				OGER		structure of LRG1	P02750		Here, we determined the crystal structure of LRG1, identifying the horseshoe-like solenoid structure of LRG1 and its four N-glycosylation sites.
36925257	6	51	gly	F1-ESP-3	1088:1095	arg1	the monosaccharide composition	ESP			the monosaccharide composition	OGER		ESP	Q6UW49		Compared with the purified component L-ESP-3, the monosaccharide composition of F1-ESP-3 contains more glucuronic acid, the molecular weight reduced from >600 kDa (L-ESP-3) to 28.30 kDa (F1-ESP-3) and 33.58 kDa (F2-ESP-3), F1-ESP-3 has higher solubility and lower apparent viscosity.
35713525	7	50	part_of	Csh1	896:899	arg1	Asn-51	Csh1		Asn-51		PUBTATOR	SpecificSite	Csh1	852458	Asn-51	Although intracellular proteins usually harbor core-type N-glycans, the N-glycan on Asn-51 of Csh1 exhibited a unique mannan-like structure containing a long backbone of mannose.
35651042	5	4	gly	TFP	794:796	arg1	free monosaccharide	TFP			free monosaccharide	OGER		TFP	Q9HCM9		However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	5	4	gly	TFP	794:796	arg1	reducing sugar content	TFP			reducing sugar content	OGER		TFP	Q9HCM9		However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	5	4	gly	TFP	794:796	arg1	constituent monosaccharide	TFP			constituent monosaccharide	OGER		TFP	Q9HCM9		However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
34695439	7	23	gly	present	1099:1105	arg1	WT TSP1 AND C-mannosylation	TSP1			C-mannosylation	PUBTATOR		TSP1	7057		C-mannosylation was variably present on WT TSP1 and increased on TSR domains 1 and 3 in KO cells.
35219398	5	48	gly	glycosylated	809:820	arg1	minimally glycosylated CCM1	minimally glycosylated CCM1				PUBTATOR		CCM1	889		We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
36830744	4	45	gly	deglycosylated	724:737	arg1	The purified IgGs	The purified IgGs				Cterm		IgGs			The purified IgGs were denatured and enzymatically deglycosylated, and the released and fluorescently labelled N-glycans were analysed by ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR).
34650217	9	24	gly	KAT5	1451:1454	arg1	O-GlcNAcylation	KAT5			O-GlcNAcylation	OGER		KAT5	Q8CHK4		Collectively, our findings demonstrate that PCK1 depletion increases O-GlcNAcylation of KAT5, epigenetically induces TWIST1 expression and promotes HCC metastasis, and link metabolic enzyme, post-translational modification (PTM) with epigenetic regulation.
36925056	4	39	gly	monosialylated	912:925	arg1	digalactosylated, monosialylated, and antennary fucosylated derived traits	digalactosylated, monosialylated, and antennary fucosylated derived traits				OGER		traits	Q96CJ1		RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36370046	1	16	gly	protein	149:155	arg1	Glycans	spike protein			Glycans	PUBTATOR		spike protein	43740568		Glycans of the SARS-CoV-2 spike protein are speculated to play functional roles in the infection processes as they extensively cover the protein surface and are highly conserved across the variants.
36637420	0	79	gly	N-glycosylation	0:14	arg1	the correct HAI-2 protein folding	HAI-2 protein				PUBTATOR		HAI-2 protein	10653		N-glycosylation on Asn-57 is required for the correct HAI-2 protein folding and protease inhibitory activity.
34012659	10	73	gly	non-N-glycosylated	1195:1212	arg1	aberrant non-N-glycosylated BST-2	aberrant non-N-glycosylated BST-2				PUBTATOR		BST-2	684		RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
37037133	6	7	gly	glycoproteins	1107:1119	arg1	donkey and human MFGM glycoproteins	donkey and human MFGM glycoproteins				OGER		MFGM glycoproteins	Q08431		The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	6	23	gly	N-glycosylation	1066:1080	arg1	donkey and human MFGM glycoproteins	donkey and human MFGM glycoproteins				OGER		MFGM glycoproteins	Q08431		The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	6	41	gly	N-glycoproteins	1211:1225	arg1	human MFGM N-glycoproteins	human MFGM N-glycoproteins				OGER		MFGM N-glycoproteins	Q08431		The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	6	63	gly	N-glycoproteins	1009:1023	arg1	human MFGM N-glycoproteins	human MFGM N-glycoproteins				OGER		MFGM N-glycoproteins	Q08431		The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
36206692	2	3	gly	Ara	522:524	arg1	Ara, Xyl, Rib, Rha	Ara			Ara, Xyl, Rib, Rha	OGER		Ara	O95255		In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
33176830	6	8	gly	N-glycosylation	1134:1148	arg1	Cav3.2	Cav3.2				PUBTATOR		Cav3.2	8912		Therefore, these newly identified asparagine residues within non-canonical motifs add to those previously reported in canonical sites and suggest that N-glycosylation of Cav3.2 may also occur at non-canonical motifs to control expression of the channel in the plasma membrane.
36580234	7	53	gly	glycosylated	1064:1075	arg1	glycosylated PD-L1	glycosylated PD-L1				PUBTATOR		PD-L1	29126		In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
35065968	0	21	gly	C	105:105	arg1	A glycan modification	flagellin C			A glycan modification	PUBTATOR		flagellin C	4916757		New insights into the type A glycan modification of Clostridioides difficile flagellar protein flagellin C by phosphoproteomics analysis.
36528711	2	46	gly	deglycosylation	350:364	arg1	human IgG	human IgG				Cterm		IgG			The Streptococcus pyogenes bacterium secretes the protease IdeS and the glycosidase EndoS, which specifically catalyse cleavage and deglycosylation of human IgG, respectively.
36813234	7	24	gly	glycoproteins	1279:1291	arg1	TNF receptor 1	TNF receptor 1				OGER		TNF receptor 1	P01375		We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	7	24	gly	glycoproteins	1279:1291	arg1	TNF receptor 2	TNF receptor 2				OGER		TNF receptor 2	P01375		We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
35773089	8	145	gly	N-acetylglucosamine	1654:1672	arg1	IgG	IgG			N-acetylglucosamine	PUBTATOR		IgG	668542		The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
32839225	13	12	gly	sialylation	2181:2191	arg1	ACO2	ACO2				PUBTATOR		ACO2	11429		These findings suggest that the switch from oxidative phosphorylation, over to glycolysis that occurs during capacitation may come about through sialylation of ACO2.
32839225	13	33	gly	ACO2	2196:2199	arg1	sialylation	ACO2			sialylation	PUBTATOR		ACO2	11429		These findings suggest that the switch from oxidative phosphorylation, over to glycolysis that occurs during capacitation may come about through sialylation of ACO2.
35871894	0	49	gly	glycoprotein	59:70	arg1	SARS-CoV-2 spike glycoprotein case study	SARS-CoV-2 spike glycoprotein case study				PUBTATOR		spike glycoprotein	43740568		Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.
36014368	4	0	gly	glycosylated	613:624	arg1	The SARS-CoV-2 S protein	The SARS-CoV-2 S protein				PUBTATOR		S protein	Q15517		The SARS-CoV-2 S protein is heavily glycosylated with 22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites.
34735575	1	21	gly	glycosylation	161:173	arg1	the spike protein	the spike protein				PUBTATOR		spike protein	43740568		Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
36290159	9	27	gly	HPA	2836:2838	arg1	O-linked glycans	HPA			O-linked glycans	OGER		HPA	Q9UL45		It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	48	gly	LTA	3098:3100	arg1	α1,2-linked fucose	LTA			α1,2-linked fucose	OGER		LTA	P01374		It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
35320529	7	36	gly	glycosylated	1103:1114	arg1	NK cell CD16a	NK cell CD16a				PUBTATOR		CD16a	2214		NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
37270132	1	16	gly	HEP-1	189:193	arg1	A low molecular weight polysaccharides	HEP			A low molecular weight polysaccharides	OGER		HEP	Q5SXM8		A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
35670884	0	7	gly	core-fucosylation	8:24	arg1	SPARC	SPARC				PUBTATOR		SPARC	6678		Loss of core-fucosylation of SPARC impairs collagen binding and contributes to COPD.
35670884	0	52	gly	SPARC	29:33	arg1	core-fucosylation	SPARC			core-fucosylation	PUBTATOR		SPARC	6678		Loss of core-fucosylation of SPARC impairs collagen binding and contributes to COPD.
34223877	1	56	gly	Peanut	146:151	arg1	a carbohydrate-binding protein	Peanut			a carbohydrate-binding protein	Cterm		Peanut			Peanut agglutinin (PNA) is a carbohydrate-binding protein in peanuts that accounts for ~0.15% peanut weight.
33119615	5	92	gly	glycosylated	943:954	arg1	mutant G82S glycosylated RAGE variants	mutant G82S glycosylated RAGE variants				OGER		RAGE variants	Q15109		Binding pocket analysis of the MD trajectory showed that cavity/binding pocket in mutant G82S glycosylated RAGE variants is more exposed and accessible to external ligands compared to WT RAGE, which can enhance the affinity of RAGE for Aβ.
37189353	4	7	gly	N-glycosylation	587:601	arg1	IgG	IgG				Cterm		IgG			To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
36791651	4	2	gly	polysaccharides	738:752	arg1	CFF	CFF			polysaccharides	OGER		CFF	P51610		In this study, a strategy integrating HPGPC-ELSD, HPLC-PDA, UV-VIS and UPLC-QTOF-MS/MS was firstly developed to simultaneously qualify and quantify polysaccharides, as well as representative small molecules in CFF.
35662639	5	70	gly	glycoproteins	1332:1344	arg1	L- amino acid oxidase	L- amino acid oxidase				OGER		L- amino acid oxidase	Q96RQ9		The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35871894	7	27	gly	glycoprotein	1117:1128	arg1	the SPIKE glycoprotein	the SPIKE glycoprotein				PUBTATOR		SPIKE glycoprotein	43740568		In this manuscript, we present a step-by-step workflow to build and perform MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion.
36959283	5	26	gly	B	894:894	arg1	quantitative N-glycan profiling	bovine pancreas ribonuclease B			quantitative N-glycan profiling	Cterm		bovine pancreas ribonuclease B			Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	5	60	gly	IgG	839:841	arg1	quantitative N-glycan profiling	IgG			quantitative N-glycan profiling	Cterm		IgG			Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
33912181	3	15	gly	glycans	454:460	arg1	TLR4	TLR4			glycans	PUBTATOR		TLR4	21898		The lectins MIC1 and MIC4 interact with N-linked glycans on TLR2 and TLR4, activating NF-κB and producing IL-12, TNF-α, and IL-6.
33912181	3	15	gly	glycans	454:460	arg1	TLR2	TLR2			glycans	PUBTATOR		TLR2	24088		The lectins MIC1 and MIC4 interact with N-linked glycans on TLR2 and TLR4, activating NF-κB and producing IL-12, TNF-α, and IL-6.
34510715	5	44	gly	enhancer	846:853	arg1	O-GlcNAc	enhancer of zeste homolog 2			O-GlcNAc	OGER		enhancer of zeste homolog 2	Q15910		PUGNAc treatment and cycloheximide (CHX) assay were performed to evaluate O-GlcNAc and the stabilization of the enhancer of zeste homolog 2 (EZH2).
33789105	6	40	gly	modification	841:852	arg3	TM/ICD AND Decreased O-GlcNAc modification	TM/ICD			Decreased O-GlcNAc modification	PUBTATOR		TM/ICD	79158		Decreased O-GlcNAc modification of TM/ICD increases the binding of E3 ubiquitin ligase Itch to TM/ICD and promotes its degradation.
33789105	6	45	gly	TM/ICD	857:862	arg1	Decreased O-GlcNAc modification	TM/ICD			Decreased O-GlcNAc modification	PUBTATOR		TM/ICD	79158		Decreased O-GlcNAc modification of TM/ICD increases the binding of E3 ubiquitin ligase Itch to TM/ICD and promotes its degradation.
36828088	5	52	gly	PSP	585:587	arg1	The monosaccharide composition	PSP			The monosaccharide composition	OGER		PSP	O00186		The monosaccharide composition of PSP contained D-xylose, d-glucose, D-galactose with ratio of 1.0: 8.3: 1.3.
36448941	8	68	gly	CMP	1306:1308	arg1	monosaccharide composition	CMP			monosaccharide composition	OGER		CMP	P21941		The purity, monosaccharide composition, molecular weight, and structural characteristics of CMP were different, but with similar infrared absorption spectra.
34952005	6	73	gly	glycosylated	1168:1179	arg1	mG6PC1	mG6PC1				PUBTATOR		G6PC1	2538		When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
33316265	12	7	gly	eNOS	1681:1684	arg1	decreased O-GlcNAc modification	eNOS			decreased O-GlcNAc modification	PUBTATOR		eNOS	24600		SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification of eNOS boosts eNOS activity in arteries of P-Wistar rats.
33316265	12	7	gly	eNOS	1681:1684	arg1	SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification	eNOS			SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification	PUBTATOR		eNOS	24600		SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification of eNOS boosts eNOS activity in arteries of P-Wistar rats.
33316265	12	8	gly	modification	1665:1676	arg3	eNOS AND decreased O-GlcNAc modification	eNOS			decreased O-GlcNAc modification	PUBTATOR		eNOS	24600		SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification of eNOS boosts eNOS activity in arteries of P-Wistar rats.
37121976	1	46	gly	ɑ-2-glycoprotein	131:146	arg1	LRG1	LRG1				OGER		LRG1	P02750		The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
33442744	6	18	part_of	Ost4	911:914	arg1	Ile24	Ost4		Ile24		PUBTATOR	AminoAcid	Ost4	851366	Ile24	Mutation of any residue from Met18 to Ile24 of Ost4 destabilizes the enzyme complex, affecting its activity.
36606688	6	47	gly	SOD3	845:848	arg1	the N-glycan	SOD3			the N-glycan	PUBTATOR		SOD3	6649		In cell lines of non-small lung cancer cell (NSCLC), we also found a high level of the core fucose structure in the N-glycan of SOD3, as determined by lectin blotting and mass spectrometry analysis.
32356523	2	39	gly	ERGIC-53	541:548	arg1	the carbohydrate-recognition domain	ERGIC-53			the carbohydrate-recognition domain	PUBTATOR		ERGIC-53	3998		It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
37037133	5	33	gly	N-glycoproteins	905:919	arg1	HM MFGM N-glycoproteins	HM MFGM N-glycoproteins				OGER		HM MFGM N-glycoproteins	Q08431		Bioinformatics was used to describe the structure-activity relationships of DC, DM, HC, and HM MFGM N-glycoproteins.
33316265	8	70	gly	eNOS	1277:1280	arg1	O-GlcNAcylation	eNOS			O-GlcNAcylation	PUBTATOR		eNOS	24600		O-GlcNAcylation of eNOS decreased in P-SHR compared to NP-SHR.
37202422	5	48	gly	afucosylated	695:706	arg1	afucosylated IgG1	afucosylated IgG1				OGER		IgG1	P01857		Here, we present the structure of one such nanobody, X0, in complex with the Fc fragment of afucosylated IgG1.
32494619	3	13	gly	O-GlcNAcylation	590:604	arg1	serine-430			serine-430	serine-430		SpecificSite			serine-430	Upon investigating the mechanisms driving this event, we determined that IAV induced OGT to bind to interferon regulatory factor-5 (IRF5), leading to O-GlcNAcylation of IRF5 on serine-430.
32494619	3	49	gly	IRF5	609:612	arg1	O-GlcNAcylation	IRF5			O-GlcNAcylation	OGER		IRF5	Q13568		Upon investigating the mechanisms driving this event, we determined that IAV induced OGT to bind to interferon regulatory factor-5 (IRF5), leading to O-GlcNAcylation of IRF5 on serine-430.